Featured Research

from universities, journals, and other organizations

Drugs are safe, active in patients normally ineligible for clinical trial, study suggests

Date:
December 10, 2010
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
A two-drug combination is safe and active in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome patients who are usually excluded from clinical trials because they have other illnesses or poor performance status -- a measure of disease progression -- researchers report.

A two-drug combination is safe and active in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome patients who are usually excluded from clinical trials because they have other illnesses or poor performance status -- a measure of disease progression -- researchers reported this week at the 52nd American Society of Hematology Annual Meeting.

Related Articles


"Our findings suggest current eligibility standards that prevent participation by these patients in phase I and phase II clinical trials might be inadequate," said Guillermo Garcia-Manero, M.D., professor in The University of Texas MD Anderson Cancer Center Department of Leukemia, who presented early results of an ongoing phase II clinical trial. Such patients also are not eligible for standard therapies.

Newly diagnosed patients with AML or MDS who have an additional disease, including a second cancer, or lack good performance status, survive for less than 60 days without treatment, Garcia-Manero said. Performance status is measured by Eastern Cooperative Oncology Group criteria, which score patients from 0 (fully active) to 4 (completely disabled).

The phase II clinical trial accepts only those with ECOG performance status higher than 2 (capable of self care, unable to work, up more than half of waking hours) and those with other diseases.

The drug combination of 5-azacitidine and vorinostat is known to be safe and active against AML and MDS among patients without the complications that participants in this trial have, Garcia-Manero said.

So far, 27 patients have been treated, nine with AML, 18 with MDS. Their median age is 69, ranging from 44 to 83. At a median follow up of 3.6 months, 20 of 24 survived past 60 days (83 percent). One patient died during therapy, two died of disease progression after going off the study.

Fifteen could be evaluated for response to the combination, seven (46 percent) had complete responses. Stable disease was noted in two patients -- one with metastatic sarcoma and one with breast cancer.

Benchmarks of survival and response that would require stopping the trial have not been met and Garcia-Manero said indications are that the study will continue and not hit either measure.

"This combination is safe and active for these poor-prognosis patients at similar levels of safety and activity seen among patients who are eligible for clinical trials," Garcia-Manero said.

Garcia-Manero and colleagues also have developed a prognostic model for MDS patients that takes into account additional diseases or conditions, called co-morbidities, to help predict survival in those patients.

Azacitidine, known commercially as Vidaza, activates genes that have been silenced by stripping them of methyl groups, which protrude like bookmarks from a gene's promoter region. Vorinostat, known commercially as Zolzinza, activates genes by protecting acetyl groups that adhere to histones -- proteins connected to DNA like beads on a string.

Both drugs reactivate enough tumor-suppressing genes to have an effect on AML and MDS.

Other investigators on the study are Elias Jabbour, M.D., Tapan Kadla, M.S., Zeev Estrov, M.D., Jorge Cortes, M.D., Patricia Ann Boone and Hagop Kantarjian, M.D., all of MD Anderson's Department of Leukemia; and Elihu Estey, M.D., Fred Hutchinson Cancer Research Center, University of Washington.

The clinical trial is supported by Merck & Co., makers of vorinostat, and Pharmion Corp., which makes azacitidine.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Drugs are safe, active in patients normally ineligible for clinical trial, study suggests." ScienceDaily. ScienceDaily, 10 December 2010. <www.sciencedaily.com/releases/2010/12/101210112331.htm>.
University of Texas M. D. Anderson Cancer Center. (2010, December 10). Drugs are safe, active in patients normally ineligible for clinical trial, study suggests. ScienceDaily. Retrieved March 2, 2015 from www.sciencedaily.com/releases/2010/12/101210112331.htm
University of Texas M. D. Anderson Cancer Center. "Drugs are safe, active in patients normally ineligible for clinical trial, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/12/101210112331.htm (accessed March 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
Going Gluten-Free Could Get You A Tax Break

Going Gluten-Free Could Get You A Tax Break

Newsy (Mar. 2, 2015) If a doctor advises you to remove gluten from your diet, you could get a tax deduction on the amount you spend on gluten-free foods. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins